- Home
- SMXT vs KPTI Comparison
SMXT vs KPTI Comparison
Compare SMXT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMXT
- KPTI
- Stock Information
- Founded
- SMXT 2008
- KPTI 2008
- Country
- SMXT United States
- KPTI United States
- Employees
- SMXT N/A
- KPTI N/A
- Industry
- SMXT
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- SMXT
- KPTI Health Care
- Exchange
- SMXT NYSE
- KPTI Nasdaq
- Market Cap
- SMXT 58.9M
- KPTI 54.4M
- IPO Year
- SMXT 2024
- KPTI 2013
- Fundamental
- Price
- SMXT $1.13
- KPTI $6.01
- Analyst Decision
- SMXT
- KPTI Strong Buy
- Analyst Count
- SMXT 0
- KPTI 5
- Target Price
- SMXT N/A
- KPTI $61.00
- AVG Volume (30 Days)
- SMXT 96.5K
- KPTI 85.6K
- Earning Date
- SMXT 05-19-2025
- KPTI 05-20-2025
- Dividend Yield
- SMXT N/A
- KPTI N/A
- EPS Growth
- SMXT N/A
- KPTI N/A
- EPS
- SMXT N/A
- KPTI N/A
- Revenue
- SMXT $22,986,881.00
- KPTI $145,237,000.00
- Revenue This Year
- SMXT N/A
- KPTI $4.87
- Revenue Next Year
- SMXT N/A
- KPTI $16.29
- P/E Ratio
- SMXT N/A
- KPTI N/A
- Revenue Growth
- SMXT N/A
- KPTI N/A
- 52 Week Low
- SMXT $0.60
- KPTI $3.51
- 52 Week High
- SMXT $13.48
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- SMXT N/A
- KPTI 51.12
- Support Level
- SMXT N/A
- KPTI $5.52
- Resistance Level
- SMXT N/A
- KPTI $7.90
- Average True Range (ATR)
- SMXT 0.00
- KPTI 0.69
- MACD
- SMXT 0.00
- KPTI 0.04
- Stochastic Oscillator
- SMXT 0.00
- KPTI 24.73
About SMXT SOLARMAX TECHNOLOGY INC
SolarMax Technology Inc is an integrated solar and renewable energy company. It operates in two segments namely the United States and China. The United States business includes the sale and installation of photovoltaic and battery backup systems. China operations consist of operating and maintaining solar farm projects and identifying and procuring solar farm projects for resale to third parties. Some of its products are LG Solar Panels, QCELL Solar Panels, Panasonic Solar Panels, and others. The company generates a majority of its revenue from the Solar energy systems.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.